The hematologist from Ohio State University Comprehensive Cancer Center–The James discussed the impact of socioeconomic factors on completion of autologous stem cell transplant in patients with mantle cell lymphoma.
This content originally appeared on our sister site, CancerNetwork.
Factors such as insurance type, treatment facility, and location are associated with chances of completing autologous stem cell transplant (ASCT), and education and race impact survival outcomes.
CancerNetwork® spoke with Yazeed Sawalha, MD, a hematologist at the Ohio State University Comprehensive Cancer Center–The James, to learn more about the impact of certain socioeconomic factors on the completion of and clinical outcomes in patients with mantle cell lymphoma.
Transcript:
We looked at the impact of demographics and socioeconomic factors on the use of ASCT, but also on clinical outcomes—specifically overall survival. We found that after adjusting for other factors, the type of insurance and specifically having private insurance rather than Medicare, as well as receiving treatment at an academic or research facility, and certain geographical locations are actually associated with higher chances of undergoing ASCT.
In terms of clinical outcomes and survival, we found that the type of insurance was also important here. In addition, higher education and income levels were also associated with superior survival, whereas Black race was associated with inferior survival.
Transplant Eligibility Versus CAR-T Eligibility
January 16th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.
Sequencing of Treatment in Third-Line R/R LBCL
January 15th 2025Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the choice between treating patients with liso-cel or bispecific T-cell engagers.